biological activity | GSK1904529A (GSK 4529) is a selective IGF-1R and IR inhibitor. in the cell-free test, IC50 is 27 nM and 25 nM respectively, acting on IGF-1R/InsR ratio acting on Akt1/2/, Aurora A/B,B-Raf, CDK2, EGFR and other selectivity is more than 100 times higher. |
target | TargetValue Insulin Receptor (Cell-free assay) 25 nM IGF-1R (Cell-free assay) 27 nM |
Target | Value |
Insulin Receptor
(Cell-free assay)
| 25 nM |
IGF-1R
(Cell-free assay)
| 27 nM |
in vitro study | GSK1904529A are selective inhibitors, and IC50 is 27 and 25 nM respectively when acting on IGF-IR and IR. GSK1904529A is a reversible ATP competitive inhibitor. When the GSK1904529A acts on IGF-IR and IR, the K I values are 1.3 and 1.6 nM respectively. GSK1904529A concentrations greater than 0.01 μM effectively inhibit IGF-IR and IR phosphorylation, and then block downstream signals. Cell proliferation experiments showed that GSK1904529A effectively inhibited NIH-3T3/LISN, TC-71, SK-N-MC, SK-ES, and RD-ES cells with IC50 of 60, 35, 43, 61, and 62 nM respectively. GSK1904529A also inhibits other multiple myeloma and Ewing's sarcoma cell lines, including NCI-H929, MOLP-8, LP-1, and KMS-12-BM. |
in vivo study | mice carrying NIH-3T3/LISN tumors were orally treated with 30mg of GSK1904529A per kilogram according to their body weight twice a day, and the results showed that the tumor inhibition rate was 98%. However, GSK1904529A acts on mice carrying COLO 205 transplanted tumors and is treated once a day, the results showed that the tumor inhibition rate was 75%. GSK1904529A can be used to treat a variety of IGF-IR-dependent tumors, including prostate cancer, colon cancer, breast cancer, pancreatic cancer, ovarian cancer, and sarcoma. |